FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064318859> ?p ?o ?g. }

• W2064318859 endingPage "365" @default.
• W2064318859 startingPage "359" @default.
• W2064318859 abstract "Four human tumor cell lines were studied for their response to antiproliferative effects of various interferons (IFNs) alone and in combination with the novel mismatched dsRNA, r(I)n r(C12,U)n (Ampligen). RT4 cells (bladder carcinoma) were resistant to Ampligen alone, while A2182 (lung carcinoma), HT1080 C14 (fibrosarcoma) and RT112 (bladder carcinoma) cells were inhibited in a dose-dependent manner. In contrast, RT4 cells were sensitive to the antitumor effects of IFNs as were HT1080 C14 and RT112 cells, while A2182 cells were resistant. In 3 of the 4 cell lines, the recombinant IFNs were less effective than the corresponding natural IFNs when compared by analysis of variance on an IRU/ml basis over a range of concentrations. In all cell lines, a synergistic antiproliferative effect was seen with all IFN preparations studied in combination with Ampligen, as calculated by the isobole method according to Berenbaum (1981). The antiproliferative effect of IFN was potentiated >3.3- to > 250-fold, depending on the cell lines, IFN, and concentrations used. Varying the concentration of βser-IFN while holding the Ampligen concentration constant gave synergy at all of the physiologically achievable concentrations tested in RT4 cells. These results indicate that: (1) Ampligen worked synergistically with all IFNs in all cell lines studied; (2) growth inhibition of cells resistant to IFNs can be potentiated by low doses of Ampligen; (3) the antiproliferative effect of IFNs can be potentiated by Ampligen in Ampligen-resistant cells; and (4) Ampligen may work by a mechanism other than, or in addition to, the induction of IFNs." @default.
• W2064318859 created "2016-06-24" @default.
• W2064318859 creator A5070106631 @default.
• W2064318859 date "1986-03-15" @default.
• W2064318859 modified "2023-09-25" @default.
• W2064318859 title "Synergistic antiproliferative effect of human interferons in combination with mismatched double-stranded RNA on human tumor cells" @default.
• W2064318859 cites W1577005558 @default.
• W2064318859 cites W1977808583 @default.
• W2064318859 cites W1987632205 @default.
• W2064318859 cites W1995578078 @default.
• W2064318859 cites W1996549520 @default.
• W2064318859 cites W1998975997 @default.
• W2064318859 cites W2005170379 @default.
• W2064318859 cites W2028853845 @default.
• W2064318859 cites W2033742158 @default.
• W2064318859 cites W2041529593 @default.
• W2064318859 cites W2075607397 @default.
• W2064318859 cites W2084929520 @default.
• W2064318859 cites W2099872899 @default.
• W2064318859 cites W2147598378 @default.
• W2064318859 cites W2269595883 @default.
• W2064318859 cites W2313658741 @default.
• W2064318859 cites W42013536 @default.
• W2064318859 cites W43237676 @default.
• W2064318859 doi "https://doi.org/10.1002/ijc.2910370306" @default.
• W2064318859 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2419265" @default.
• W2064318859 hasPublicationYear "1986" @default.
• W2064318859 type Work @default.
• W2064318859 sameAs 2064318859 @default.
• W2064318859 citedByCount "20" @default.
• W2064318859 countsByYear W20643188592023 @default.
• W2064318859 crossrefType "journal-article" @default.
• W2064318859 hasAuthorship W2064318859A5070106631 @default.
• W2064318859 hasConcept C1491633281 @default.
• W2064318859 hasConcept C153911025 @default.
• W2064318859 hasConcept C185592680 @default.
• W2064318859 hasConcept C202751555 @default.
• W2064318859 hasConcept C203014093 @default.
• W2064318859 hasConcept C2776178377 @default.
• W2064318859 hasConcept C2776495794 @default.
• W2064318859 hasConcept C2777751087 @default.
• W2064318859 hasConcept C2779707156 @default.
• W2064318859 hasConcept C3020616263 @default.
• W2064318859 hasConcept C502942594 @default.
• W2064318859 hasConcept C54355233 @default.
• W2064318859 hasConcept C55493867 @default.
• W2064318859 hasConcept C62112901 @default.
• W2064318859 hasConcept C81885089 @default.
• W2064318859 hasConcept C86803240 @default.
• W2064318859 hasConceptScore W2064318859C1491633281 @default.
• W2064318859 hasConceptScore W2064318859C153911025 @default.
• W2064318859 hasConceptScore W2064318859C185592680 @default.
• W2064318859 hasConceptScore W2064318859C202751555 @default.
• W2064318859 hasConceptScore W2064318859C203014093 @default.
• W2064318859 hasConceptScore W2064318859C2776178377 @default.
• W2064318859 hasConceptScore W2064318859C2776495794 @default.
• W2064318859 hasConceptScore W2064318859C2777751087 @default.
• W2064318859 hasConceptScore W2064318859C2779707156 @default.
• W2064318859 hasConceptScore W2064318859C3020616263 @default.
• W2064318859 hasConceptScore W2064318859C502942594 @default.
• W2064318859 hasConceptScore W2064318859C54355233 @default.
• W2064318859 hasConceptScore W2064318859C55493867 @default.
• W2064318859 hasConceptScore W2064318859C62112901 @default.
• W2064318859 hasConceptScore W2064318859C81885089 @default.
• W2064318859 hasConceptScore W2064318859C86803240 @default.
• W2064318859 hasIssue "3" @default.
• W2064318859 hasLocation W20643188591 @default.
• W2064318859 hasLocation W20643188592 @default.
• W2064318859 hasOpenAccess W2064318859 @default.
• W2064318859 hasPrimaryLocation W20643188591 @default.
• W2064318859 hasRelatedWork W1579080780 @default.
• W2064318859 hasRelatedWork W1770611506 @default.
• W2064318859 hasRelatedWork W1988491573 @default.
• W2064318859 hasRelatedWork W1995100484 @default.
• W2064318859 hasRelatedWork W2064318859 @default.
• W2064318859 hasRelatedWork W2071608724 @default.
• W2064318859 hasRelatedWork W2085612853 @default.
• W2064318859 hasRelatedWork W2357174515 @default.
• W2064318859 hasRelatedWork W2413532914 @default.
• W2064318859 hasRelatedWork W3140728205 @default.
• W2064318859 hasVolume "37" @default.
• W2064318859 isParatext "false" @default.
• W2064318859 isRetracted "false" @default.
• W2064318859 magId "2064318859" @default.
• W2064318859 workType "article" @default.